{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:07:14Z","timestamp":1762430834460,"version":"3.40.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00228-013-1605-6","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T13:10:28Z","timestamp":1383743428000},"page":"135-140","source":"Crossref","is-referenced-by-count":14,"title":["Putative effects of potentially anti-angiogenic drugs in rheumatic diseases"],"prefix":"10.1007","volume":"70","author":[{"given":"Nicola","family":"Maruotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ribatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,7]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353\u2013364","journal-title":"Cell"},{"key":"1605_CR2","doi-asserted-by":"crossref","first-page":"i65","DOI":"10.1136\/ard.59.suppl_1.i65","volume":"59","author":"AE Koch","year":"2000","unstructured":"Koch AE (2000) The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 59:i65\u2013i71","journal-title":"Ann Rheum Dis"},{"key":"1605_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2009.02.002","volume":"51","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Koch AE (2009) Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51:1\u20137","journal-title":"Vascul Pharmacol"},{"key":"1605_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.humpath.2003.11.010","volume":"35","author":"K Takahara","year":"2004","unstructured":"Takahara K, Iioka T, Furukawa K, Uchida T, Nakashima M, Tsukazaki T, Scindo H (2004) Autocrine\/paracrine role of the angiopoietin-1 and \u22122\/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum Pathol 35:150\u2013158","journal-title":"Hum Pathol"},{"key":"1605_CR5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI4891","volume":"103","author":"S Tanaka","year":"1999","unstructured":"Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341\u2013345","journal-title":"J Clin Invest"},{"key":"1605_CR6","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1074\/jbc.273.11.6417","volume":"273","author":"NS Levy","year":"1998","unstructured":"Levy NS, Chung S, Furneaux H, Levy AP (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417\u20136423","journal-title":"J Biol Chem"},{"key":"1605_CR7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0002-9440(10)63259-2","volume":"165","author":"YW Park","year":"2004","unstructured":"Park YW, Mo Kang Y, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087\u20132098","journal-title":"Am J Pathol"},{"key":"1605_CR8","doi-asserted-by":"crossref","first-page":"630620","DOI":"10.1155\/2013\/630620","volume":"2013","author":"T Yamamoto","year":"2013","unstructured":"Yamamoto T (2013) Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol 2013:630620","journal-title":"ISRN Dermatol"},{"key":"1605_CR9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ncprheum0647","volume":"3","author":"Z Szekanecz","year":"2007","unstructured":"Szekanecz Z, Koch AE (2007) Mechanism of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 3:635\u2013643","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1605_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tcm.2012.05.011","volume":"21","author":"M Manetti","year":"2011","unstructured":"Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2011) Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 21:204\u2013210","journal-title":"Trends Cardiovasc Med"},{"key":"1605_CR11","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","volume":"109","author":"M Manetti","year":"2011","unstructured":"Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M (2011) Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 109:e14\u201326","journal-title":"Circ Res"},{"key":"1605_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art1.10161","volume":"47","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2002","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Garc\u00eda-Mart\u00ednez A, Casademont J, Filella X, Esteban MJ, L\u00f3pez-Soto A, Fern\u00e1ndez-Sol\u00e0 J, Urbano-M\u00e1rquez A, Grau JM, Cid MC (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29\u201335","journal-title":"Arthritis Rheum"},{"key":"1605_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1078\/0065-1281-00621","volume":"104","author":"K Halacheva","year":"2002","unstructured":"Halacheva K, Gulubova MV, Manolova I, Petkov D (2002) Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 104:177\u2013184","journal-title":"Acta Histochem"},{"key":"1605_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1582-4934.2002.tb00514.x","volume":"6","author":"E Bodolay","year":"2002","unstructured":"Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z (2002) Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 6:357\u2013376","journal-title":"J Cell Mol Med"},{"key":"1605_CR15","first-page":"303","volume":"28","author":"B Yacin","year":"2006","unstructured":"Yacin B, Arda N, Tezel GG, Erman M, Alli N (2006) Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet\u2019s disease. Anal Quant Cytol Histol 28:303\u2013306","journal-title":"Anal Quant Cytol Histol"},{"key":"1605_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/keh344","volume":"44","author":"CS Bonnet","year":"2005","unstructured":"Bonnet CS, Walsh DA (2005) Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44:7\u201316","journal-title":"Rheumatology (Oxford)"},{"key":"1605_CR17","doi-asserted-by":"crossref","first-page":"R326","DOI":"10.1186\/ar1182","volume":"6","author":"AY Goedkoop","year":"2004","unstructured":"Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP (2004) Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 6:R326\u2013R334","journal-title":"Arthritis Res Ther"},{"key":"1605_CR18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2006.01.038","volume":"54","author":"T Markham","year":"2006","unstructured":"Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ (2006) Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54:1003\u20131012","journal-title":"J Am Acad Dermatol"},{"key":"1605_CR19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/art.21016","volume":"52","author":"Y Chen","year":"2005","unstructured":"Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC (2005) Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52:1585\u20131594","journal-title":"Arthritis Rheum"},{"key":"1605_CR20","doi-asserted-by":"crossref","first-page":"ii60","DOI":"10.1136\/ard.62.suppl_2.ii60","volume":"62","author":"AE Koch","year":"2003","unstructured":"Koch AE (2003) Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62:ii60\u2013ii67","journal-title":"Ann Rheum Dis"},{"key":"1605_CR21","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082\u20134085","journal-title":"Proc Natl Acad Sci USA"},{"key":"1605_CR22","first-page":"1596","volume":"29","author":"J Versapuech","year":"2000","unstructured":"Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596\u20131599","journal-title":"Presse Med"},{"key":"1605_CR23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1525-1470.2001.018002143.x","volume":"18","author":"R Brik","year":"2001","unstructured":"Brik R, Shamali H, Bergman R (2001) Successful thalidomide treatment of severe infantile Beh\u00e7et disease. Pediatr Dermatol 18:143\u2013145","journal-title":"Pediatr Dermatol"},{"key":"1605_CR24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/sj.leu.2403852","volume":"19","author":"D Ribatti","year":"2005","unstructured":"Ribatti D, Vacca A (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19:1525\u20131531","journal-title":"Leukemia"},{"key":"1605_CR25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/1529-0131(199801)41:1<122::AID-ART15>3.0.CO;2-8","volume":"41","author":"I Siegle","year":"1998","unstructured":"Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P (1998) Expression of cyclooxygenase-2 in human synovial tissue. Arthritis Rheum 41:122\u2013129","journal-title":"Arthritis Rheum"},{"key":"1605_CR26","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.91.6.2046","volume":"91","author":"JR Vane","year":"1994","unstructured":"Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA (1994) Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 91:2046\u20132050","journal-title":"Proc Natl Acad Sci USA"},{"key":"1605_CR27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0014-4800(03)00019-4","volume":"74","author":"JM Woods","year":"2003","unstructured":"Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE (2003) The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74:282\u2013290","journal-title":"Exp Mol Pathol"},{"key":"1605_CR28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF03401768","volume":"4","author":"BP Eliceiri","year":"1998","unstructured":"Eliceiri BP, Cheresh DA (1998) The role of alphav integrins during angiogenesis. Mol Med 4:741\u2013750","journal-title":"Mol Med"},{"key":"1605_CR29","first-page":"455","volume":"23","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T (2005) Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 23:455\u2013461","journal-title":"Clin Exp Rheumatol"},{"key":"1605_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejphar.2007.03.057","volume":"567","author":"L Yue","year":"2007","unstructured":"Yue L, Shen YX, Feng LJ, Chen FH, Yao HW, Liu LH, Wu Q, Wang H (2007) Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 567:166\u2013170","journal-title":"Eur J Pharmacol"},{"issue":"136","key":"1605_CR31","doi-asserted-by":"crossref","first-page":"136ra71","DOI":"10.1126\/scitranslmed.3003421","volume":"4","author":"Y Yamaguchi","year":"2012","unstructured":"Yamaguchi Y, Takihara T, Chambers RA, Veraldi KL, Larregina AT, Feghali-Bostwick CA (2012) A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med 4(136):136ra71","journal-title":"Sci Transl Med"},{"key":"1605_CR32","first-page":"2171","volume":"34","author":"CR Wang","year":"2007","unstructured":"Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, Chao L, Chao J (2007) Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 34:2171\u20132176","journal-title":"J Rheumatol"},{"key":"1605_CR33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/art.20991","volume":"52","author":"CR Wang","year":"2005","unstructured":"Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J (2005) Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 52:1319\u20131324","journal-title":"Arthritis Rheum"},{"key":"1605_CR34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcp.20958","volume":"211","author":"MC Rico","year":"2007","unstructured":"Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA (2007) Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP-1-derived peptide treatment. J Cell Physiol 211:504\u2013512","journal-title":"J Cell Physiol"},{"key":"1605_CR35","first-page":"580","volume":"27","author":"N Bessis","year":"1998","unstructured":"Bessis N, Boissier MC (1998) Gene therapy in rheumatoid polyarthritis: perspectives. Presse Med 27:580\u2013582","journal-title":"Presse Med"},{"key":"1605_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20995","volume":"116","author":"M Saito","year":"2005","unstructured":"Saito M, Murata T, Watanabe K et al (2005) Adenoviral vector-mediated gene transfer of IL-13R_2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers. Int J Cancer 116:1\u20138","journal-title":"Int J Cancer"},{"key":"1605_CR37","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/art.22034","volume":"54","author":"CS Haas","year":"2006","unstructured":"Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK III, Woods JM, Koch AE (2006) Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54:2402\u20132414","journal-title":"Arthritis Rheum"},{"key":"1605_CR38","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/art.22823","volume":"56","author":"CS Haas","year":"2007","unstructured":"Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE (2007) In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 56:2535\u20132548","journal-title":"Arthritis Rheum"},{"key":"1605_CR39","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.gt.3302104","volume":"10","author":"AO Afuwape","year":"2003","unstructured":"Afuwape AO, Feldmann M, Paleolog EM (2003) Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 10:1950\u20131960","journal-title":"Gene Ther"},{"key":"1605_CR40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet P, Ferreira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435\u2013439","journal-title":"Nature"},{"key":"1605_CR41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761\u2013772","journal-title":"Nat Rev Cancer"},{"key":"1605_CR42","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1158\/1078-0432.CCR-03-0795","volume":"10","author":"G Kaur","year":"2004","unstructured":"Kaur G, Belotti D, Burger AM et al (2004) Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10:4813\u20134821","journal-title":"Clin Cancer Res"},{"key":"1605_CR43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.molcel.2007.01.001","volume":"25","author":"YV Liu","year":"2007","unstructured":"Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL (2007) RACK1 competes with HSP90 for binding to HIF-1\u03b1 and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1\u03b1. Mol Cell 25:207\u2013217","journal-title":"Mol Cell"},{"key":"1605_CR44","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1161\/01.ATV.0000147894.22300.4c","volume":"24","author":"J Sun","year":"2004","unstructured":"Sun J, Liao JK (2004) Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 24:2238\u20132244","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1605_CR45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/ar3045","volume":"12","author":"G Nagy","year":"2010","unstructured":"Nagy G, Koncz A, Telarico T, Fernandez D, Ersek B, Buz\u00e1s E, Perl A (2010) Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 12:210","journal-title":"Arthritis Res Ther"},{"key":"1605_CR46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","volume":"1823","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742\u2013755","journal-title":"Biochim Biophys Acta"},{"key":"1605_CR47","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/art.24047","volume":"58","author":"JW Rice","year":"2008","unstructured":"Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE (2008) Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58:3765\u20133775","journal-title":"Arthritis Rheum"},{"key":"1605_CR48","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.bjc.6601591","volume":"90","author":"CR Ireson","year":"2004","unstructured":"Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D et al (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90:932\u2013937","journal-title":"Br J Cancer"},{"key":"1605_CR49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10456-007-9081-1","volume":"10","author":"TL Khong","year":"2007","unstructured":"Khong TL, Larsen H, Raatz Y, Paleolog E (2007) Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 10:243\u2013258","journal-title":"Angiogenesis"},{"key":"1605_CR50","first-page":"95","volume":"56","author":"CG Moertel","year":"1972","unstructured":"Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95\u2013101","journal-title":"Cancer Chemother Rep"},{"key":"1605_CR51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00011-007-7163-6","volume":"57","author":"JK Jackson","year":"2008","unstructured":"Jackson JK, Higo T, Hunter WL, Burt HM (2008) Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res 57:126\u2013134","journal-title":"Inflamm Res"},{"key":"1605_CR52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s11095-010-0330-4","volume":"28","author":"OM Koo","year":"2011","unstructured":"Koo OM, Rubinstein I, Ony\u00fcksel H (2011) Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res 28:776\u2013787","journal-title":"Pharm Res"},{"key":"1605_CR53","first-page":"CR616","volume":"8","author":"M Pache","year":"2002","unstructured":"Pache M, Schwarz HA, Kaiser HJ, Wuest P, Kloti M, Dubler B, Flammer J (2002) Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 8:CR616\u2013CR619","journal-title":"Med Sci Monit"},{"key":"1605_CR54","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.50.7.526-c","volume":"50","author":"H Julkunen","year":"1991","unstructured":"Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F (1991) Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 50:526\u2013527","journal-title":"Ann Rheum Dis"},{"key":"1605_CR55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbapap.2007.07.013","volume":"1784","author":"AJ Melendez","year":"2008","unstructured":"Melendez AJ (2008) Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta 1784:66\u201375","journal-title":"Biochim Biophys Acta"},{"key":"1605_CR56","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/art.21668","volume":"54","author":"M Kitano","year":"2006","unstructured":"Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, Iwasaki T, Sano H, Saba JD, Tam YY (2006) Sphingosine 1-phosphate\/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum 54:742\u2013753","journal-title":"Arthritis Rheum"},{"key":"1605_CR57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s000110050608","volume":"49","author":"M Matsuura","year":"2000","unstructured":"Matsuura M, Imayoshi T, Chiba K, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 49:404\u2013410","journal-title":"Inflamm Res"},{"key":"1605_CR58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.mehy.2012.05.019","volume":"79","author":"A Sheikh","year":"2012","unstructured":"Sheikh A, Naqvi SH, Naqvi SH, Sheikh K (2012) Itraconazole: its possible role in inhibiting angiogenesis in rheumatoid arthritis. Med Hypotheses 79:313\u2013314","journal-title":"Med Hypotheses"},{"key":"1605_CR59","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","volume":"71","author":"BT Aftab","year":"2011","unstructured":"Aftab BT, Dobromilskaya I, Liu JO, Rudin CM (2011) Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 71:6764\u20136772","journal-title":"Cancer Res"},{"key":"1605_CR60","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2174\/138161206777698747","volume":"12","author":"J Bainbridge","year":"2006","unstructured":"Bainbridge J, Sivakumar B, Paleolog E (2006) Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des 12:2631\u20132644","journal-title":"Curr Pharm Des"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1605-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:40:57Z","timestamp":1746042057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,7]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1605-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2013,11,7]]}}}